Literature DB >> 25563595

Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument.

José Ramiro Espinoza-Zamora1, César Miguel Portilla-Espinosa, Juan Rafael Labardini-Méndez, Eduardo Cervera, Ruben Niesvisky, Luis F Oñate-Ocaña.   

Abstract

Health-related quality of life (HRQL) has become an important outcome measurement in hematology. Our aim was to validate the quality of life questionnaire (QLQ)-MY20 instrument in patients with multiple myeloma (MM) in Mexico. The Mexican-Spanish versions of the QLQ-C30 and QLQ-MY20 instruments were applied to patients with MM at a cancer referral centre. Reliability and validity tests were performed. Test-retest was carried out in selected patients. Ninety-eight patients with MM were included in this study. Questionnaire compliance rates were high, and the instrument was well accepted; internal consistency tests demonstrated good convergent and divergent validity. Cronbach's α coefficients of seven of nine multi-item scales of the QLQ-C30 and of all three multi-item scales of the QLQ-MY20 instruments were >0.7 (range, 0.36-0.89). The scales of the QLQ-C30 and QLQ-MY20 instruments distinguished among clinically distinct groups of patients; 9 of 15 scales of the QLQ-C30 and all 4 scales of the QLQ-MY20 presented responsiveness after change over time. The Mexican-Spanish version of the QLQ-MY20 questionnaire is reliable and valid for the assessment of HRQL in patients with MM and can be used in clinical trials in the Mexican community.

Entities:  

Mesh:

Year:  2015        PMID: 25563595     DOI: 10.1007/s00277-014-2290-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  2 in total

1.  Quality of life assessment & out-of-pocket expenditure in multiple myeloma: An observational study.

Authors:  Anisha Mathew; Habib Hasan Farooqui; Lalit Kumar
Journal:  Indian J Med Res       Date:  2021-06       Impact factor: 5.274

2.  Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.

Authors:  Pushpendra Goswami; Esther N Oliva; Tatyana Ionova; Roger Else; Jonathan Kell; Adele K Fielding; Daniel M Jennings; Marina Karakantza; Saad Al-Ismail; Graham P Collins; Stewart McConnell; Catherine Langton; Sam Salek
Journal:  Front Pharmacol       Date:  2020-03-05       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.